已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

PKCβII–ACSL4 pathway mediating ferroptosis execution and anti‐tumor immunity

免疫 癌症研究 化学 心理学 生物 分子生物学 免疫学 免疫系统
作者
Guang Lei,Amber D. Horbath,Li Zhuang,Boyi Gan
出处
期刊:癌症:英文版 卷期号:42 (7): 583-586 被引量:40
标识
DOI:10.1002/cac2.12319
摘要

Ferroptosis is an iron-dependent form of regulated cell death that results from oxidative damages of membrane phospholipids, and is mechanistically and morphologically unique compared to other cell death modalities, such as apoptosis and necroptosis [1]. Excessive ferroptosis is indicative of many pathological conditions, including cardiovascular diseases, neurodegenerative diseases, and acute organ injury, whereas ferroptosis impairment has been shown to fuel tumor progression and metastasis; therefore, targeting ferroptosis represents a promising strategy for treating these diseases [2-10]. Ferroptosis is triggered by a lethal accumulation of lipid peroxides on the cell membrane. Cells have evolved effective antioxidant defense systems to counteract membrane damages caused by lipid peroxidation and escape from their ferroptotic fate. The most potent defense system is powered by glutathione peroxidase 4 (GPX4), a peroxidase that requires glutathione as its cofactor to quench the otherwise toxic lipid peroxides [11]. This ferroptosis defense system can be overridden by ferroptosis inducers (FINs) that inactivate GPX4 or deplete glutathione pools in cells; consequently, ferroptosis defense systems collapse and ferroptosis ensues [12]. Polyunsaturated-fatty-acid-containing phospholipids (PUFA-PLs), particularly arachidonic acid (AA)- and adrenic acid (AdA)-containing PLs, are critical for triggering lipid peroxidation [12]. To be incorporated into PLs, AAs and AdAs are first catalyzed by acyl-coenzyme A synthetase long-chain family member 4 (ACSL4) to generate their acyl-coenzyme A (CoA) derivatives (AA-CoA and AdA-CoA) [13]. These PUFA-CoAs are further integrated into PLs to form PUFA-PLs by lysophosphatidylcholine acyltransferase 3 (LPCAT3) and other enzymes [14]. Due to their unstable double bonds, PUFAs are especially vulnerable to peroxidation within reactive oxygen species (ROS)- and iron-rich cellular environments, driving lipid peroxidation chain reactions in PUFA-PLs in the cellular membrane through the Fenton reaction and other enzymes, and ultimately resulting in membrane rupture and ferroptotic cell death if left unchecked by ferroptosis defense systems [12]. However, the sensing and amplification mechanisms of lipid peroxidation remain poorly understood, and whether or how ACSL4 is activated in ferroptosis remains elusive. In fact, ACSL4-mediated PUFA-PL synthesis is generally believed to operate in a passive way to constitutively provide substrates for lipid peroxidation. Protein kinase C (PKC) constitutes a family of protein kinases, including eight PKC isozymes (namely PKCα, PKCβΙ, PKCβΙΙ, PKCγ, PKCδ, PKCɛ, PKCθ and PKCη), which control the activity of downstream proteins by phosphorylating their serine/threonine residues [15]. PKCs play important roles in a wide variety of cellular processes, such as cell proliferation, cell survival/death, and oxidative stress responses [15]. Notably, PKCs have been shown to promote ROS generation [15, 16]. The increased levels of ROS can further amplify PKC signaling, thus forming a positive feedback loop [17]. Given that ferroptosis is a form of oxidative stress-induced cell death, one interesting question is whether PKCs are also engaged in lipid peroxidation and ferroptosis. A recent study by Zhang et al. [18] showed that lipid peroxidation activates PKCβII; subsequently, the activated PKCβII further amplifies lipid peroxidation by phosphorylating and activating ACSL4, constituting a lipid peroxidation-PKCβII-ACSL4 positive feedback loop for ferroptosis execution. The authors set out to identify novel ferroptosis regulatory genes by using CRISPR- Cas9 screening, through which they uncovered several known ferroptosis regulators, such as ACSL4, GPX4, Kelch-like ECH-associated protein 1 (KEAP1), and Poly(RC) Binding Protein 1 (PCBP1), thereby validating the robustness of their CRISPR screens [18]. Of note, PKCβ was identified as a top suppressor hit (whose deficiency suppresses ferroptosis and whose guide RNAs were enriched upon FIN treatment) with previously unknown function in ferroptosis. The authors also showed that PKC inhibitors exerted the strongest inhibitory effect on ferroptosis among 644 compounds from a kinase inhibitor library [18]. Furthermore, they excluded the potential involvement of other PKC isoforms, such as PKCα, PKCγ, PKCδ and PKCζ, in regulating ferroptosis, and found that only PKCβII isoform contributed directly to the susceptibility of cancer cells to ferroptosis: cancer cell lines with high levels of PKCβII were generally more sensitive to ferroptosis than those with low levels of PKCβII, and PKCβII deficiency resulted in resistance to FIN-induced lipid peroxidation and ferroptosis [18]. Interestingly, Zhang et al. [18] showed that FINs could induce PKCβII activation by promoting its phosphorylation and membrane localization, and lipophilic radical-trapping antioxidants completely inhibited PKCβII activation, indicating that lipid peroxidation is vital for PKCβII activation. These findings raised an intriguing possibility that PKCβII might act as a lipid peroxidation sensor and prompted the question of how PKCβII is engaged in lipid peroxidation and ferroptosis. As noted above, the ferrous-catalyzed Fenton reaction is required for lipid peroxidation and ferroptosis [12]. In addition, inactivation of GPX4-mediated ferroptosis defense promotes an overload of lipid peroxides and ferroptosis [11, 12]. Zhang et al. [18] therefore tested the potential connection of PKCβII to iron and GPX4, but found that PKCβII inactivation did not affect GPX4 levels or cellular ferrous levels. Instead, they showed that PKCβII was capable of interacting with ACSL4 and directly phosphorylating ACSL4 at Thr328. ACSL4 Thr328 phosphorylation was increased during ferroptotic stress, which could be inhibited by PKCβII deletion or inactivation; likewise, blocking PKCβII activation by scavenging lipid peroxides restrained FIN-induced phosphorylation of ACSL4 at Thr328 [18]. Mechanistically, the authors revealed that PKCβII-mediated ACSL4 phosphorylation at Thr328 is imperative for the dimerization of ACSL4 (which represents the activation form of ACSL4) [18]. Therefore, they speculated that PKCβII-mediated ACSL4 phosphorylation activates ACSL4, thereby promoting PUFA-PL generation and ferroptosis. In support of this hypothesis, non-targeted lipidomic analyses established that FINs increased PUFA-PL generation in ACSL4 wild-type cells, but not in ACSL4-Thr328Ala mutant-expressing cells, and that PKCβII inhibition impaired FIN-induced increases of PUFA-PL levels in ACSL4 wild-type cells. Furthermore, phosphorylation of ACSL4 at Thr328 was found to be important for ACSL4-mediated AA/AdA-CoA biosynthesis. Consistently, FINs induced less potent lipid peroxidation and ferroptosis in ACSL4-Thr328Ala mutant-expressing cells than in ACSL4 wild-type counterparts [18]. Together, these analyses provide compelling evidence that PKCβII-mediated phosphorylation of ACSL4 at Thr328 is critical for ACSL4 activation and ferroptosis execution. On the basis of these findings, the authors proposed a positive feedback loop model for lipid peroxidation and ferroptosis execution, wherein PKCβII senses lipid peroxidation and can be activated by lipid peroxides, and its activation further promotes ACSL4 dimerization and activity by phosphorylating the Thr328 site in ACSL4 to enhance PUFA-PL synthesis and amplify the accumulation of lipid peroxides to a lethal level, resulting in ferroptosis (Figure 1). To place their findings in the context of ferroptosis-associated diseases, Zhang et al. [18] investigated the potential role of ACSL4 Thr328 phosphorylation in ferroptosis-related ischemia-reperfusion. ACSL4 Thr328 phosphorylation was found to increase progressively during ischemia-reperfusion, suggesting that this phosphorylation may serve as a ferroptosis biomarker in this pathological model and that targeting the PKCβII-ACSL4 axis is likely to be a potential strategy for treating patients with ischemia-reperfusion injury. Ferroptosis has been shown to partly mediate CD8+ T cell-mediated antitumor immunity [6]. Specifically, interferon-gamma (IFNγ) secreted by CD8+ T cells can downregulate the Solute Carrier Family 7 Member 11(SLC7A11)-mediated cystine uptake and glutathione synthesis in cancer cells, thereby promoting lipid peroxidation and ferroptosis [6]. A recent study by Liao et al. [19] demonstrated that IFNγ could also stimulate ACSL4 expression through signal transducer and activator of transcription 1 (STAT1)-interferon regulatory factor 1 (IRF1) signaling, thereby promoting ACSL4-mediated synthesis of PUFA-PLs (particularly AA-containing PLs) to boost ferroptosis. Therefore, although AA or IFNγ alone does not trigger strong ferroptosis, AA in combination with IFNγ can synergistically induce potent tumoral ferroptosis. Furthermore, ACSL4 deficiency impaired T cell-mediated anti-tumor responses, thereby hastening tumor progression, suggesting that ACSL4 can control anti-tumor immunity by modulating tumoral ferroptosis [19]. Importantly, low doses of AA could enhance anti-tumor immunity by promoting ferroptosis and increase the sensitivity of tumors to immune checkpoint inhibitors (ICIs). Furthermore, the analysis of tumor samples from patients showed that higher ACSL4 expression was associated with higher scores of T cell-mediated anti-tumor immunity and may be correlated with better clinical responses of these patients to immunotherapy [19]. These results were confirmed by Zhang et al. [18] who demonstrated a positive correlation between ACSL4 expression in tumors and the sensitivity of corresponding tumors to ICIs in a cohort of melanoma patients. Moreover, preclinical models showed that Thr328 phosphorylation-inactivating mutation in ACSL4 or PKCβII deletion compromised the efficacy of ICIs by suppressing ferroptosis. These results indicate that PKCβII-ACSL4 pathway-mediated PUFA-PL production and ferroptosis execution are critical for T cell-mediated anti-tumor immunity (Figure 1). Collectively, the study by Zhang et al. [18] proposed the importance of a positive feedback loop by the lipid peroxidation-PKCβII-ACSL4 pathway in sensing and amplifying lipid peroxidation, and revealed that PKCβII activation is required for ACSL4 activation and ferroptosis execution. Together, Zhang et al. [18] and Liao et al. [19] suggested that ACSL4 expression may serve as a predictor for immunotherapy responses in cancer patients and that targeting the PKCβII-ACSL4 pathway in combination with ICIs might be a promising strategy for cancer therapy (Figure 1). These studies also raised several outstanding questions. In addition to PUFA-PLs, PUFA-containing ether phospholipids (PUFA-ePLs) are also important substrates for lipid peroxidation [20]. Whether PKCβII can sense and amplify the accumulation of PUFA-ePL peroxides and therefore regulate ferroptosis remains a fascinating area for future studies. It will be also interesting to study exactly how lipid peroxidation promotes PKCβII activation during ferroptotic stress. Importantly, this study challenges the conventional view that ACSL4-mediated PUFA-PL synthesis promotes ferroptosis in a passive and incidental manner. Whether there exist other regulatory mechanisms that actively participate in ferroptosis execution awaits further investigations. Finally, from a therapeutic perspective, it remains to be established whether there exist appropriate therapeutic windows for PKCβII activators (or AA) in combination with different ICIs to selectively kill tumors without inducing obvious toxicities in normal tissues. Whether targeting the PKCβII-ACSL4 pathway can be effective in treating other ferroptosis-related diseases, such as acute kidney injury or degenerative diseases, also deserves further exploration. Research in the authors' lab has been supported by The University of Texas MD Anderson Cancer Center, National Institutes of Health grants R01CA181196, R01CA244144, and R01CA247992, and Cancer Prevention & Research Institute of Texas grant RP220258 (to Boyi Gan), and by Cancer Center Support (Core) Grant P30 CA016672 from the National Cancer Institute (to The University of Texas MD Anderson Cancer Center). Boyi Gan is an inventor of patent applications involving targeting ferroptosis in cancer therapy. Other authors have no conflicts of interest to declare. Guang Lei and Amber Horbath drafted the manuscript. Boyi Gan provided critical revision of the manuscript with additional manuscript editing support from Zhuang Li. All authors read and approved the final manuscript. Not applicable. Not applicable. Not applicable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星睿发布了新的文献求助10
刚刚
liang完成签到 ,获得积分10
1秒前
机智的紫菜完成签到,获得积分10
2秒前
zzoUo完成签到 ,获得积分10
2秒前
2秒前
CCCms完成签到,获得积分10
2秒前
babayega发布了新的文献求助10
2秒前
555完成签到,获得积分10
3秒前
4秒前
mmmm发布了新的文献求助140
5秒前
脑洞疼的应助被Luxie采纳,获得10
5秒前
疯狂的奎发布了新的文献求助40
6秒前
6秒前
7秒前
852的应助被感动的易真采纳,获得10
8秒前
CJ完成签到,获得积分10
8秒前
Aj发布了新的文献求助10
9秒前
9秒前
赘婿的应助被gyh采纳,获得10
10秒前
余香的应助被www采纳,获得10
10秒前
yzr01发布了新的文献求助10
11秒前
11秒前
12秒前
JamesPei的应助被可口可乐乐采纳,获得20
12秒前
耍酷季节的应助被机智的紫菜采纳,获得30
12秒前
Mingway完成签到,获得积分10
12秒前
12秒前
tutu完成签到,获得积分10
12秒前
pine完成签到,获得积分10
12秒前
无奈醉柳发布了新的文献求助10
13秒前
Zora完成签到 ,获得积分10
13秒前
余香的应助被ArtemkaChem采纳,获得10
14秒前
慕青的应助被犹豫紫蓝采纳,获得10
14秒前
15秒前
Mingway发布了新的文献求助10
15秒前
16秒前
纯真的翠彤的应助被wyz采纳,获得10
16秒前
16秒前
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158064
求助须知:如何正确求助?哪些是违规求助? 9553987
关于积分的说明 21716926
捐赠科研通 7747422
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471057